Status:
UNKNOWN
Weight Based Enoxaparin in Trauma Patients
Lead Sponsor:
Intermountain Health Care, Inc.
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Hospitalized trauma patients frequently suffer from blood clots in the legs or lungs. To minimize the risk of these blood clots developing, patients may be given a blood-thinner drug such as enoxapari...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Body Weight \>60 kg
- Admitted to the trauma services at Intermountain Medical Center
- Have received 1 standard dose of enoxaparin for VTE prophylaxis during current hospital admission.
Exclusion
- Significant bleeding injury such as solid organ laceration or intracranial bleed at discretion of attending physician
- Renal insufficiency (GFR \<30)
- Platelet count \<100 thousand per cubic ml
- Hypersensitivity to heparin or prior documented heparin induced thrombocytopenia (HIT) by patient report or in medical record
- Pregnant or breast feeding
- Hemorrhagic stroke in proceeding 3 months
- abnormal baseline coagulation characterized by an INR \>1.4, obtained at the discretion of the treating clinician
- Required therapeutic anticoagulation for atrial fibrillation, prior VTE, or mechanical heart valve
- Treatment with concomitant antiplatelet agent other than aspirin 326 mg or more daily
- Subjects with a life expectancy less than 1 month
- Subjects hospitalized more than 72 hours prior to randomization.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT01916707
Start Date
July 1 2013
End Date
December 1 2017
Last Update
April 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intermountain Medical Center
Murray, Utah, United States, 84157-7000